Summary
Pfizer Inc. (PFE) filed an 8-K on June 17, 2003, to disclose financial projections and information presented to securities analysts. The report highlights the combined company's pro-forma revenue and earnings per share growth expectations following the merger with Pharmacia Corporation, which was completed on April 16, 2003. Investors can glean forward-looking insights into Pfizer's anticipated financial trajectory.
Key Highlights
- 1Pfizer will hold a meeting with securities analysts on June 17, 2003, to present financial information related to the Pharmacia merger.
- 2Pro-forma combined revenue for Pfizer/Pharmacia in 2002 was approximately $45 billion.
- 3Pfizer projects a compound annual revenue growth rate of approximately 10% from 2002 to 2004, reaching $54 billion in 2004.
- 4Adjusted diluted earnings per share are projected to grow at a 16% compound annual rate from 2002 to 2004, reaching $2.13 in 2004.
- 5A reconciliation is provided for Pfizer's reported 2002 revenues to the pro-forma combined revenue, showing an adjustment to eliminate intercompany transactions.
- 6Pfizer will file pro-forma financial statements related to the Pharmacia acquisition by June 30, 2003.
- 7A visual aid containing this information is attached as Exhibit 99.